Form 4: Artiva SVP Gains 46,000 RSUs, Sells Shares for Tax

Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, received a restricted stock unit award and sold shares to cover tax obligations.

Summary

• Heather Raymon, SVP, Research and Development at Artiva Biotherapeutics, Inc. (ARTV), reported transactions on February 15, 2026.
• Acquired 46,000 shares of Common Stock as a restricted stock unit (RSU) award under the company's 2024 Equity Incentive Plan.
• Disposed of 1,521 shares of Common Stock at a price of $4 per share to satisfy income tax obligations related to RSU vesting.
• Following these transactions, Raymon beneficially owns 151,323 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting ongoing executive incentive alignment through equity awards, which is a standard and healthy practice for public companies.

Positives

• Grant of 46,000 restricted stock units (RSUs) to a key executive, Heather Raymon, indicating continued alignment of management incentives with shareholder interests.
• The RSU award is part of the Issuer's 2024 Equity Incentive Plan, suggesting ongoing use of equity compensation to attract and retain talent.

Negatives

• Disposition of 1,521 shares of common stock, although for tax purposes, reduces the executive's direct ownership.

Future Outlook

This Form 4 does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that equity compensation, such as restricted stock units, is a standard practice in the biotechnology and pharmaceutical industries to incentivize key research and development personnel, aligning their long-term interests with company performance. The tax-related sale is a common occurrence upon RSU vesting.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a Senior Vice President of Research and Development is a common compensation practice across the biotech sector, comparable to similar grants observed at companies like Moderna, BioNTech, or Gilead Sciences for their R&D leadership.
• The disposition of shares to cover tax obligations upon RSU vesting is a standard and expected event, not indicative of a discretionary sale, and is consistent with practices seen at virtually all publicly traded companies that utilize equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to continued alignment of executive incentives with company performance.
• Employees: Reflects the company's use of equity compensation, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 details a routine executive compensation event involving the grant of restricted stock units and a subsequent tax-related sale. Such transactions are common and do not typically signal a fundamental change in the company's prospects or warrant a strong buy or sell recommendation based solely on this filing. It primarily indicates ongoing executive incentive alignment.

Keywords

Artiva Biotherapeutics, ARTV, Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Incentive Plan, Executive Compensation, Heather Raymon